Back to Search
BRIAN LUM, PHARM.D.
PHARM.D.
Pharmacist
NPI: 1245466747Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
61816(CA)
Research & Publications (20)
Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
PMID 10755319·Cancer Chemother Pharmacol·2000
3-trial
Effect of diabetic retinopathy and panretinal photocoagulation on retinal nerve fiber layer and optic nerve appearance.
PMID 19597104·Arch Ophthalmol·2009
4-observational
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
PMID 19415281·Cancer Chemother Pharmacol·2009
3-trial
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
PMID 19299235·Clin Breast Cancer·2009
3-trial
Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
PMID 18205003·Cancer Chemother Pharmacol·2008
8-other
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.
PMID 18176118·Anticancer Drugs·2008
2-rct
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
PMID 18000659·Eur J Clin Pharmacol·2008
2-rct
Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.
PMID 17549476·Cancer Chemother Pharmacol·2008
7-preclinical
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
PMID 16890575·Clin Pharmacol Ther·2006
3-trial
Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
PMID 16715358·Pharm Res·2006
4-observational
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
PMID 16490804·J Clin Pharmacol·2006
3-trial
Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
PMID 16381666·Drug Metab Dispos·2006
8-other
Quantitative structure-activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance-associated protein 2 (rMrp2).
PMID 16154329·Eur J Pharm Sci·2005
7-preclinical
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
PMID 16133798·Invest New Drugs·2005
3-trial
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.
PMID 16126736·Ann Oncol·2005
3-trial
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
PMID 15475439·Clin Cancer Res·2004
3-trial
Quantitative structure-pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k-nearest-neighbor and partial least-square analysis methods.
PMID 15349962·J Pharm Sci·2004
8-other
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
PMID 15301879·Lung Cancer·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4501 BROADWAY
OAKLAND, CA 94611 - Phone
- (510) 407-7914
Quick Facts
- NPI
- 1245466747
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile